SVB Leerink Lowers Arcus Biosciences’ PT to $38.00

Trending News 🌧️

ARCUS BIOSCIENCES ($NYSE:RCUS) is a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer and other diseases.

Price History

SVB Leerink lowered Arcus Biosciences‘ PT to $38.00 on Friday, citing mostly neutral news sentiment surrounding the company. The stock opened at $24.9 and closed at $24.4 on the day.

VI Analysis

Companies with strong fundamentals generally have a higher long-term potential than those with weak fundamentals.

However, even companies with strong fundamentals can be high-risk investments. The VI Risk Rating is a comprehensive assessment of a company’s financial and business risk. It takes into account a number of factors, including the company’s balance sheet, cash flow statement, and financial journal. The VI App has detected 3 risk warnings in the balance sheet, cash flow statement, and financial journal of ARCUS BIOSCIENCES. These warnings indicate that the company may be at risk of financial distress in the future.

VI Peers

The company’s product candidates include AB928, AB154 and AB122, which are in various clinical trials for the treatment of solid tumors and hematologic malignancies. Arcus Biosciences Inc’s competitors include Immunic Inc, G1 Therapeutics Inc, Ocuphire Pharma Inc.

– Immunic Inc ($NASDAQ:IMUX)

The company’s market cap is $56.93M as of 2022 and its ROE is -44.31%. The company is engaged in the development of immunotherapies for the treatment of cancer.

– G1 Therapeutics Inc ($NASDAQ:GTHX)

G1 Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapies for the treatment of cancer. The company’s lead product candidate is trilaciclib, which is in clinical development for the treatment of small cell lung cancer (SCLC) and triple-negative breast cancer (TNBC). Trilaciclib is a first-in-class cyclin-dependent kinase 4/6 (CDK4/6) inhibitor that selectively targets proliferating cancer cells and spares normal cells. CDK4/6 inhibitors are a new class of anti-cancer drugs that block the activity of two proteins that are involved in cell division.

G1 Therapeutics has a market cap of $366.9 million and a return on equity of -159.15%. The company’s lead product candidate is trilaciclib, which is in clinical development for the treatment of small cell lung cancer (SCLC) and triple-negative breast cancer (TNBC). Trilaciclib is a first-in-class cyclin-dependent kinase 4/6 (CDK4/6) inhibitor that selectively targets proliferating cancer cells and spares normal cells. CDK4/6 inhibitors are a new class of anti-cancer drugs that block the activity of two proteins that are involved in cell division.

– Ocuphire Pharma Inc ($NASDAQ:OCUP)

Ocuphire Pharma Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing therapies to treat ocular disorders. Its lead product candidate is Nyxol, a once-daily eye drop for the treatment of glaucoma and ocular hypertension. The company was founded by Derek J. Rappaport and Nancy S. Lurie on March 1, 2006 and is headquartered in Boca Raton, FL.

Summary

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on developing cancer immunotherapies. The company’s stock trades on the Nasdaq under the ticker symbol “RCUS.” Investors interested in Arcus Biosciences may want to consider the company as a potential investment. However, the stock is still considered a risky investment due to the company’s clinical-stage status and the inherent risks associated with investing in biotech companies.